Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line
treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a
clinically relevant benefit for subjects with advanced gastric adenocarcinoma including
gastroesophageal junction (GEJ) adenocarcinoma, in terms of progression free survival (PFS).
Secondary objectives are to assess cetuximab plus XP versus XP alone with respect to overall
survival, overall tumor response, quality of life (QoL) and safety.